

Alphagan[®] P (brimonidine) – First-time generic

- On September 2, 2023, [Apotex launched](#) an [AB-rated](#) generic version of Allergan's [Alphagan P \(brimonidine\)](#) 0.1% ophthalmic solution.
 - Alembic received [FDA approval](#) of AB-rated generic Alphagan P on August 1, 2023. Launch plans are pending.
- Alphagan P is approved for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Brimonidine is also available generically as [0.15%](#) and [0.2%](#) ophthalmic solutions, topical [gel](#), and in combination with [timolol](#) as an ophthalmic solution, and as a brand ophthalmic combination brimonidine/brinzolamide ([Simbrinza[®]](#)), and as an over-the-counter ophthalmic solution [Lumify[®]](#).
 - Brimonidine ophthalmic solution 0.15% and 0.2% and Simbrinza carry the same indication as Alphagan P 0.1%.
 - Brimonidine topical gel is approved as topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.
 - Brimonidine/timolol is approved for the reduction of elevated IOP in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.
 - Lumify should be used for relieving redness of the eye due to minor eye irritations.